Rising Osteoporosis Prevalence and Advances in Biologics Propel Market Expansion Globally

The growing incidence of osteoporosis and associated fractures, particularly in aging populations across the globe, is the main factor propelling the market. The need for efficient bone health treatments has grown dramatically as a result of longer life expectancies and an aging population. Treatment results are being improved and adoption is being accelerated by developments in biologics, anabolic agents, and regenerative medicine. Demand is also being increased by greater knowledge of early diagnosis, bone density screening programs, and preventative healthcare. Access to cutting-edge treatments is also being improved by growing healthcare infrastructure and reimbursement assistance in both developed and emerging nations.

Awareness Gaps Regulatory Hurdles and Slow Adoption May Hamper Market Expansion Globally

Lack of knowledge and diagnosis in some areas, which causes treatment to be delayed, is a major barrier to the market for anti-osteoporosis therapy and fracture healing. Faster market growth is also hampered by regulatory barriers for novel biologics and cell-based therapies, worries about long-term therapeutic adverse effects, and conservative healthcare systems' sluggish embrace of creative fracture healing techniques.

Major Companies in the Anti-Osteoporosis Therapy and Fracture Healing Market Include:

• Amgen Inc.
• Eli Lilly and Company
• Novartis AG
• Pfizer Inc.
• Merck and Co., Inc.
• F. Hoffmann-La Roche Ltd (Roche)
• GlaxoSmithKline plc (GSK)
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Johnson and Johnson Services, Inc.
• Radius Health, Inc.
• UCB S.A.
• Daiichi Sankyo Company, Limited
• Sun Pharmaceutical Industries Ltd.
• Entera Bio Ltd.
• Allergan plc
• Takeda Pharmaceutical Company Limited
• Cipla Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Other Participants

Segmentation Analysis:

By Drug Type

Bisphosphonates dominated with 47.63% in 2025E due to their proven efficacy, widespread clinical use, and strong availability as first-line treatments for osteoporosis. Monoclonal Antibodies is expected to grow at the fastest CAGR of 8.03% from 2026 to 2033 driven by advancements in biologic therapies, superior fracture prevention efficacy, increasing approvals of novel agents, and growing adoption of targeted treatments.

By Route of Administration

Oral dominated with 71.47% in 2025E due to its convenience, patient preference, ease of use, and widespread availability of effective oral bisphosphonates. Injectable is expected to grow at the fastest CAGR of 7.46% from 2026 to 2033 driven by advancements in biologics and monoclonal antibodies, such as romosozumab and denosumab.

By Distribution Channel

Hospital Pharmacies dominated with 6.30% in 2025E due to their central role in dispensing prescription-based therapies, biologics, and specialized fracture healing treatments. Online Pharmacies is expected to grow at the fastest CAGR of 8.86% from 2026 to 2033 driven by growing digital health adoption, increased e-commerce penetration, convenience of home delivery, and expanding telemedicine services.

By Fracture Healing Type

Allograft dominated with 48.46% in 2025E due to its wide clinical adoption, proven effectiveness, availability, and established use in orthopedic surgeries for bone repair and regeneration. Cell-based Therapies is expected to grow at the fastest CAGR of 7.76% from 2026 to 2033 driven by advancements in regenerative medicine, stem cell research, and tissue engineering, offering superior bone healing, personalized treatment approaches, and improved long-term patient outcomes.